Immatics Archives

Interview 26 May 2021

Immuno-Oncology: From Science Fiction to the Mainstream

In just a couple of decades, immuno-oncology has taken center stage in the biotechnology industry. We discuss the evolution of the field with experts who have been in it from…

May 26, 2021 - 7 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 28 Dec 2020

A Year to Remember: The Biggest European Biotech News in 2020

The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. …

December 28, 2020 - 12 minutesmins - By Jonathan Smith

News and Trends 13 Aug 2020

Why are Some European Biotechs Going Public Without an IPO?

European biotech companies are flocking to the Nasdaq Stock Market in 2020, but not all are going the traditional Initial Public Offering (IPO) route. What does this mean for the…

August 13, 2020 - 7 minutesmins - By Jonathan Smith

News and Trends 20 Feb 2020

Immatics Partners GSK in Deal Worth €1B to Develop Cancer Therapies

The German biotech Immatics will partner with GSK and could receive more than €1B from the big pharma for developing cancer immunotherapies based on engineered immune T-cells. Immatics will collaborate…

February 20, 2020 - 3 minutesmins - By Jonathan Smith

Expert Advice 7 Sep 2019

Why Being in a New Field From the Start Can Pay Off in the Long Run

The field of immuno-oncology has expanded out of all recognition over the last few years. Having co-founded one of the first cancer immunotherapy biotechs -- Immatics -- CEO Harpreet Singh…

September 7, 2019 - 12 minutesmins - By Helen Albert

celgene immatics cancer cell immunotherapy

News and Trends 28 Aug 2019

Celgene and Immatics Sign Deal Worth Over €1.35B to Develop Cancer Immunotherapies

The US company Celgene has obtained options to three cancer immunotherapy programs from the German biotech Immatics in a deal worth more than €1.35B ($1.5B). Immatics is to receive an…

August 28, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 20 Dec 2018

Personalized Immunotherapy for Brain Cancer Succeeds in Clinical Trials

A European trial has proved the feasibility and efficacy of treating cancer with a personalized immunotherapy tailored to each patient. The phase I/II trial, run across six European centers, tested…

December 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 20 Feb 2018

Money, Money, Money! Europe’s Best-Funded Biotechs in 2018

Besides struggling with ambitious New Year’s resolutions and post-holiday diets, January is a time where many of us re-examine our finances and budget for the year ahead. With money on…

February 20, 2018 - 11 minutesmins - By Karen O’Hanlon Cohrt

immatics amgen fundraising cancer immunotherapy

News and Trends 4 Oct 2017

Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy

Immatics has completed a $58M (€50M) round with the participation of Amgen, not long after both companies signed a billion-dollar partnership. Immatics, a company based in Tübingen specialized in cancer immunotherapy, has…

October 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Sep 2017

German Pharma Enters the Clinic with Solid Tumor Treatment

A Phase I study will investigate the safety and tolerability of Immatics approach to treating solid tumors. Immatics is a German biopharma based in Tuebingen, which is a leader in…

September 28, 2017 - 2 minutesmins - By Alex Dale

Immatics cancer personalized cell therapy

News and Trends 21 Aug 2017

German Biotech Starts Trials with a Personalized Cell Therapy for Multiple Cancers

Immatics will start a first clinical trial to test IMA101, a personalized cell therapy with the potential to treat multiple types of solid tumors. Based in Tübingen, Germany, Immatics has announced…

August 21, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Infographics 13 Feb 2017

Infographic: What’s in Europe’s Immuno-oncology Pipeline?

While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer. What new therapies are European biotech cooking up? Since the…

February 13, 2017 - 2 minutesmins - By Evelyn Warner

Screenshot 2017 01 09 at 12.40.51 PM e1483962109441

News and Trends 9 Jan 2017

German Immuno-Oncology Biotech partners up with Biotech Giant Amgen

Immatics and Amgen have inked a deal to develop bispecific drug candidates for cancer that could reach over €1B in milestones. Immatics, an immuno-oncology biotech in Tübingen, Germany, has signed an agreement…

January 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 25 Aug 2015

Leading German Biotechs MorphoSys and Immatics partner to pump up their Immuno-Oncology Therapies

Two German biotechs with highly successful platforms join forces to fight cancer. MorphoSys and Immatics Biotechnologies want to generate novel antibody-based therapeutics against multiple cancer antigens. They are two of…

August 25, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 20 Oct 2014

European’s First Personalized Vaccines to Treat Brain Cancer

A novel concept of fully personalized therapeutic cancer vaccines, called Glioma Actively Personalized VAccine Consortium (GAPVAC), has been moved into the clinic. It is the first european approval for such a…

October 20, 2014 - 3 minutesmins - By Julie Lellouche

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering